Designing a malaria vaccine
Considerable progress has been made in the 20 years since the first malaria vaccine trials were conducted in establishing the feasibility of and capacity for vaccine development. Nevertheless, there is still not a single vaccine that is likely to be introduced into control programmes in the foreseeable future. The reasons are many and complex. Forty per cent of the world's population lives at risk from malaria but it is not a uniform risk. The heartland of malaria is Africa south of the Sahara where 90% of the 500 million clinical cases and most of the 2-3 million deaths each year occur. This does not mean that the burden of disease elsewhere in the world is not severe; the seemingly inexorable spread of drug resistance is nowhere more advanced than in parts of southeast Asia. The main aim of vaccination is to eliminate or lessen the occurrence of clinical disease. Because of the complexity of the life cycle of Plasmodium spp, there are several different ways in which this can be attempted, and most of them are under extensive study.' Sporozoite invasion and intrahepatic development Infection occurs when an infected mosquito injects sporozoites that circulate briefly in the blood but must then penetrate liver parenchyma cells. Considerable attention has been focused on the sporozoites as vaccine targets because when attenuated by radiation they provide strong protection against subsequent sporozoite induced challenge. The immunogenic circumsporozoite protein (CSP) on the sporozoite surface contains a long series of tandem repeats of amino acids. In Plasmodium falciparum this consists of about 40 copies of the sequence asparagine-alanineasparagine-proline (NANP). Natural given three doses of the vaccine together with a potent adjuvant consisting of oil in water emulsion, monophosphoryl lipid A and Quillaia saponin; six of the volunteers were completely protected against subsequent challenge with the homologous parasite.' The numbers are small but the results are encouraging and a phase I/II field trial is to be performed in African adults. The success or failure of the field trials, in the face of heterologous strain challenge, may depend on whether protection is mediated by the response to the conserved tandem repeats or the polymorphic T cell epitopes.
The one phase of the malaria life cycle at which a cytotoxic T cell response could be effective is during intrahepatic development and, while its feasibility as a vaccine strategy has yet to be established, it is being investigated with in vitro presentation of epitopes from selected liver stage antigens.6
Blood stage vaccines The products of development in the liver, the merozoites, invade erythrocytes. Here, further asexual cycles of multiplication and merozoite release occur every two or three days and these are responsible for the pathogenic effects that cause clinical disease and, in P falciparum, death. In principle, there are various ways in which vaccination could be used to modulate this phase of the life cycle. The surface of the infected erythrocyte is greatly modified, and expressed parasite antigens can be targeted to achieve antibody-mediated removal of the affected red blood cells. P falciparum blood stage trophozoites and schizonts cytoadhere to endothelial cells as a natural part of their development; blocking this ability to bind would enhance parasite clearance; however, the P falciparum erythrocyte membrane protein 1 (Pf EMP 1) molecules that mediate binding constitute a large family of proteins characterised by their great variability.7 It is a feature of these blood stages that antigens are polymorphic, and the parasite has the capacity for extensive antigenic variation.
Most attention at this stage of infection has focused on molecules that are involved in initial invasion of erythrocytes by merozoites. Two of these, apical merozoite antigen 1 (AMA 1) and merozoite surface protein 2 (MSP 2), plus a third antigen (Pfl 55/RESA), are currently in a clinical vaccine trial. A further antigen, MSP 1, is considered by some to be the best vaccine candidate for invasion inhibition. It is cleaved into fragments during merozoite formation; the C-terminal portion remains on the surface of the penetrating merozoite, and antibody responses to it have been shown to correlate with protective immunity.8
An MSP 1 N-terminal sequence is one of the four components of the polymerised synthetic peptide SPf 66, the one P falciparum candidate vaccine to have been tested extensively in clinical trials. The other components are NANP repeats from the circumsporozoite protein, and sequence from two blood stage antigens, Pf35 and Pf55, about which little is known. The vaccine gave 30-35% protection against clinical malaria in trials in South America, where transmission is low, and in 1-5 year old children in Tanzania where transmission is intense.9 By contrast, no protection was demonstrable when infants under 1 year old were vaccinated in The Gambia'" or in 1-15 year olds in Thailand." A further trial in infants is underway in Tanzania as this is the age group in Africa most at risk. While the concept of combining epitopes from different antigens and stages is a good one, this particular peptide is unlikely to be used outside South America, and even here will probably be superseded.
Multiple antigen-epitope-gene approach The multiple antigen-epitope-gene approach to malaria vaccine development is widely perceived as the only way to achieve good antiparasitic and disease immunity. An important element of such an approach is likely to be an immune response to the sexual cycle that begins with the male and female gametocytes produced in the blood and is completed within the feeding mosquito. In an article referred to by Stewart, Valente says candidly that one of the goals of proficiency testing is to "weed out the incompetent", although he points out that there is no evidence that proficiency testing improves laboratory performance.3 He also says that "common sense would indicate that the recognition of accepted diagnostic criteria is a valid measure of competence" and that "we must not lose sight of the education role of proficiency testing".' Stewart suggests that internal quality control, accreditation, and comparison of performance and outcome might equally or even better be able to identify poor performance. Is an external assessment needed as well?
Stewart must be justified in saying that there is no evidence that mortality from cervical cancer is affected by proficiency testing. Laboratory performance would have to be uniformly substandard for a long time to be reflected in mortality, which is difficult to compare in small populations. More to the point, he says that proficiency does not reflect laboratory false negative rates. Sensitivity of primary screening is proportional to the number of abnormalities known to be present4 and would be expected to be high in a set of 10 slides almost half of which were known to be abnormal. Sensitivity of primary screening can be monitored by re-screening negative slides, but ultimately
